BWEL intervention with diet and weight loss is able to improve:
✅metabolic biomarkers
✅insulin resistance
✅ stress biomarkers
BWEL study presented by Dr. Jennifer Ligibel. Looking forward to future data with improved breast cancer outcomes. @dfcibreastonc.bsky.social #SABCS24

Phase I clinical trials: it is important to get the dose as right as possible prior to phase III clinical trials. @fda.gov project OPTIMUS focus on totality of data for improved dose decision making:
- minimize toxicity
- enhance efficacy
- improve outcome for patients
#SABCS24 #clinicaltrials

Can we bring 2L PFS closer to 12 months post 1L CDK4/6i? More work needed to improve biomarkers for selection of optimal 2L therapeutic option. #ESMOASIA24

The largest oncology conference in Asia with over 4,000 participants is about to start. #ESMOAsia24 Singapore

There is not enough evidence for poor performance of cdk4/6i (abema in MonarchE) in patients with BRCA pathogenic mutations. These patients still
deserve adj cdk4/6i if they meet criteria. Nadia Harbeck discussing this topic in Bogota 🇨🇴